A Phase 2, Randomized, Double-Blind, Placebo Controlled, 3-Period Crossover, Positive Control, QT-Evaluation Study of APL-130277 in Subjects with Parkinson's Disease Complicated by Motor Fluctuations (“OFF” Episodes)

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo Controlled, 3-Period Crossover, Positive Control, QT-Evaluation Study of APL-130277 in Subjects with Parkinson's Disease Complicated by Motor Fluctuations (“OFF” Episodes)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Apomorphine (Primary) ; Moxifloxacin
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Cynapsus Therapeutics; Sunovion Pharmaceuticals
  • Most Recent Events

    • 28 Sep 2017 Planned End Date changed from 30 Sep 2017 to 15 Dec 2017.
    • 28 Sep 2017 Planned primary completion date changed from 30 Sep 2017 to 15 Dec 2017.
    • 05 Sep 2017 Planned number of patients changed from 45 to 42.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top